dyslipidemia
Conditions
Interventions
For patients with dyslipidemia whose management target values are not achieved even with standard treatment, a dyslipidemia treatment support app is added to standard treatment.
Sponsors
Uchida Daigaku
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients whose fasting/casual LDL-C exceeds the lipid management target value by risk category (*) or whose fasting/casual TG (neutral fat) is 150-499/175-499 mg/dl (2)Patients whose medication for dyslipidemia and diabetes has not changed since the last visit, and who do not plan to change it for 12 weeks after the start of the study (3)Patients who can use a smartphone with iOS 14 or above or Android 10 or above and carry it on a daily basis (4)Patients who are 18 years old or older and younger than 75 years old at the time of obtaining consent, and who are able to obtain written consent from the patient to participate in this study (*) Lipid management target values by risk category (*) are based on the 2022 edition of the Arteriosclerotic Disease Prevention Guidelines. Low risk LDL-C: <160, non-HDL-C: <190, TG: <175 (as needed), <150 (fasting) (mg/dl) Medium risk LDL-C: <140, non-HDL-C: <170, TG: <175 (anytime), <150 (fasting) (mg/dl) High risk LDL-C: <120, non-HDL-C: <150, TG: <175 (anytime), <150 (fasting) (mg/dl) Have risk factors even among high risk+ (e.g. diabetes + microangiopathy) LDL-C: <100, non-HDL-C: <130, TG: <175 (anytime), <150 (fasting) (mg/dl)
Exclusion criteria
Exclusion criteria: (1)Patients on secondary prevention (with a history of coronary artery disease) (2)Patients with TG 500mg/dl or more (3)Patients with familial hyperlipidemia (4)Patients who do not have, use, or carry a smartphone with iOS 14 or higher or Android 10 or higher on a daily basis (5)Patients who are currently participating in other clinical trials or specific clinical studies involving intervention, or who are planning to participate within the trial period of this study. (6)Patients with severe liver damage (7)Patients who are scheduled to be hospitalized or undergo surgery during this study (8)Patients whose family members or partners who live together are already participating in this study (9)Pregnant women, patients who may be pregnant, or who do not agree to perform an appropriate pregnancy method within the study period (10)Patients with a disease such as dementia that makes it difficult to obtain consent and use the app appropriately (11)Patients who have alcohol or drug abuse or dependence, or unstable psychiatric illness, and who are judged to be ineligible as subjects for this study by the research physician at the conducting medical institution. (12)Patients who are instructed or need to be instructed to restrict exercise of moderate intensity or higher due to a disease other than dyslipidemia. (13)Patients with a history of fractures due to osteoporosis (14)Patients currently undergoing treatment for a malignant tumor. (15)Patients with serious infections (16)Patients whose inclusion in this study is deemed inappropriate by the research physician at the conducting medical institution
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events (adverse events) associated with app use (events, causal relationships, incidence rates, etc.) | — |
Contacts
Public ContactDaigaku Uchida
Hotaruno central clinic
Outcome results
None listed